COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III
Status:
Terminated
Trial end date:
2020-07-22
Target enrollment:
Participant gender:
Summary
The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized
infectious disease of the respiratory tract. Most cases are mild or asymptomatic. However,
around 5% of all patients develop Acute Respiratory Distress Syndrome (ARDS), which is the
leading mortality cause in these patients. Corticosteroids have been tested in deferent
scenarios of ARDS, including viral pneumonia, and the early use of dexamethasone is safe and
appears to reduce the duration of mechanical ventilation in ARDS patients. Nevertheless, no
large, randomized, controlled trial was performed evaluating the role of corticosteroids in
patients with ARDS due SARS-CoV2 virus. Therefore, the present study will evaluate the
effectiveness of dexamethasone compared to control (no corticosteroids) in patients with
moderate and severe ARDS due to SARS-CoV2 virus.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital Sirio-Libanes Luiz F. L. Reis, Ph.D.
Collaborators:
Ache Laboratorios Farmaceuticos S.A. Brazilian Research In Intensive Care Network Hospital do Coracao Hospital Israelita Albert Einstein